Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4249112
Max Phase: Preclinical
Molecular Formula: C37H56O4
Molecular Weight: 564.85
Molecule Type: Small molecule
Associated Items:
ID: ALA4249112
Max Phase: Preclinical
Molecular Formula: C37H56O4
Molecular Weight: 564.85
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CCC[C@](C)([C@H]2CC[C@]3(C)[C@@H]2[C@H](O)C[C@@H]2[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4[C@@H](OCc4ccccc4)C[C@]23C)O1
Standard InChI: InChI=1S/C37H56O4/c1-32(2)17-12-18-37(8,41-32)25-15-20-35(6)30(25)26(38)21-28-34(5)19-16-29(39)33(3,4)31(34)27(22-36(28,35)7)40-23-24-13-10-9-11-14-24/h9-11,13-14,25-28,30-31,38H,12,15-23H2,1-8H3/t25-,26+,27-,28+,30-,31-,34+,35+,36+,37+/m0/s1
Standard InChI Key: SJBJFBWDCMUDLX-MXZDGIIYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 564.85 | Molecular Weight (Monoisotopic): 564.4179 | AlogP: 8.14 | #Rotatable Bonds: 4 |
Polar Surface Area: 55.76 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 7.25 | CX LogD: 7.25 |
Aromatic Rings: 1 | Heavy Atoms: 41 | QED Weighted: 0.40 | Np Likeness Score: 2.50 |
1. Wu Q, Chen P, Tu G, Li M, Pan B, Guo Y, Zhai J, Fu H.. (2018) Synthesis and evaluation of panaxatriol derivatives as Na+, K+-ATPase inhibitors., 28 (17): [PMID:30049579] [10.1016/j.bmcl.2018.07.027] |
Source(1):